Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

OABI

OmniAb Inc

Feb 13 • 04:00PM ET

1.70

+0.01 0.59 %

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ONC EBS FOLD KURA MGNX ADAP XBIT ONCT

| Held by: VTI IWM VXF IBB IWN VTWO SCHA IWC VHT DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.59	Insider Own	24.25%	Shs Outstand	143.96M	Perf Week	0.00%
Market Cap	244.73M	Forward P/E	-	EPS next Y	-0.39	Insider Trans	0.09%	Shs Float	109.04M	Perf Month	-10.99%
Enterprise Value	206.30M	PEG	-	EPS next Q	-0.09	Inst Own	42.40%	Short Float	5.35%	Perf Quarter	8.28%
Income	-63.67M	P/S	11.60	EPS this Y	11.27%	Inst Trans	8.43%	Short Ratio	11.79	Perf Half Y	-15.00%
Sales	21.09M	P/B	0.88	EPS next Y	27.69%	ROA	-19.86%	Short Interest	5.84M	Perf YTD	-8.11%
Book/sh	1.93	P/C	4.11	EPS next 5Y	23.56%	ROE	-22.37%	52W High	4.02 -57.71%	Perf Year	-53.30%
Cash/sh	0.41	P/FCF	-	EPS past 3/5Y	-22.79% -	ROIC	-21.61%	52W Low	1.22 39.34%	Perf 3Y	-55.44%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.76% -	Gross Margin	8.77%	Volatility	7.74% 6.62%	Perf 5Y	-
Dividend TTM	-	EV/Sales	9.78	EPS Y/Y TTM	5.16%	Oper. Margin	-321.85%	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.00	Sales Y/Y TTM	3.36%	Profit Margin	-301.83%	RSI (14)	39.44	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.00	EPS Q/Q	9.94%	SMA20	-6.93%	Beta	0.16	Target Price	7.33
Payout	-	Debt/Eq	0.08	Sales Q/Q	-46.33%	SMA50	-10.77%	Rel Volume	0.72	Prev Close	1.69
Employees	114	LT Debt/Eq	0.06	Earnings	Nov 04 AMC	SMA200	-2.45%	Avg Volume	495.03K	Price	1.70
IPO	Sep 30, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-1.67% -48.98%	Trades		Volume	354,488	Change	0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-29-23	Initiated	RBC Capital Mkts	Outperform	$6
Apr-21-23	Initiated	The Benchmark Company	Buy	$8
Apr-13-23	Initiated	Craig Hallum	Buy	$10
Feb-22-23	Initiated	Cowen	Outperform	$10
Feb-13-23	Initiated	H.C. Wainwright	Buy	$11
Dec-20-22	Initiated	Truist	Buy	$10
Dec-16-22	Initiated	Credit Suisse	Outperform	$13
Nov-29-22	Initiated	SVB Leerink	Outperform	$6
Nov-28-22	Initiated	Stifel	Buy	$12

Dec-15-25 04:05PM	Launch of OmniUltra Expands OmniAb's Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies (Business Wire) -5.58%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire) +8.00%
Dec-04-25 04:05PM	OmniAb to Hold OmniUltra Virtual Investor Event on December 15 (Business Wire)
Nov-17-25 05:23PM	OmniAb Enters into a Technology License and Services Agreement for Antibody Discovery with a Newly-Formed Incubated Company of ArrowMark Partners and Viking Global Investors (Business Wire) +5.92%
Nov-05-25 12:06AM	OmniAb Inc (OABI) Q3 2025 Earnings Call Highlights: Strong Program Momentum Amid Revenue Decline (GuruFocus.com)
06:35PM	Loading…
Nov-04-25 06:35PM	OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	OmniAb Reports Third Quarter 2025 Financial Results and Business Highlights (Business Wire)
Nov-03-25 08:07AM	What To Expect From OmniAb Inc (OABI) Q3 2025 Earnings (GuruFocus.com)
Oct-30-25 10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 10:00AM	OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-16-25 08:55AM	Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains? (Zacks)
08:00AM	OmniAb to Participate in Three Investor Conferences in November (Business Wire)
Oct-14-25 08:00AM	OmniAb to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Sep-02-25 08:00AM	OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-25-25 07:00AM	OmniAb Announces $30 Million Private Placement (Business Wire) -11.89%
06:15PM	Loading…
Aug-06-25 06:15PM	OmniAb, Inc. (OABI) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.39%
04:05PM	OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights (Business Wire)
Aug-05-25 10:26AM	OmniAb Inc (OABI) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Jul-16-25 08:00AM	OmniAb to Report Second Quarter 2025 Financial Results on August 6 (Business Wire)
Jun-30-25 09:50AM	AI Is Quietly Reinventing Healthcare--And Real Deployments Are Now Underway (PR Newswire)
May-13-25 04:05PM	OmniAb Showcases Innovative High-Throughput Single B-cell Screening xPloration Platform at the 21st Annual PEGS Boston Summit (Business Wire) +8.57%
May-09-25 08:31AM	Is OmniAb, Inc. (OABI) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) -8.28%
May-08-25 05:40PM	OmniAb, Inc. (OABI) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:06PM	OmniAb Reports First Quarter 2025 Financial Results and Business Highlights (Business Wire)
04:05PM	OmniAb Introduces the xPloration® Partner Access Program (Business Wire)
May-05-25 12:59PM	VERAXA Biotech Enters Co-discovery Alliance with OmniAb for a Novel Bispecific Antibody Drug Conjugate Program (GlobeNewswire)
May-01-25 08:00AM	OmniAb to Participate in Five Upcoming Investor Conferences (Business Wire)
Apr-21-25 08:00AM	OmniAb Announces Two New Appointments to its Board of Directors (Business Wire)
Apr-14-25 08:00AM	OmniAb to Report First Quarter 2025 Financial Results on May 8 (Business Wire)
Mar-18-25 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights (Business Wire) -20.38%
08:00AM	Loading…
Feb-24-25 08:00AM	OmniAb to Report Fourth Quarter 2024 Financial Results on March 18 (Business Wire)
Feb-03-25 04:57PM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-16-24 04:15PM	OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering and Therapeutics Conference (Business Wire)
Nov-12-24 04:05PM	OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights (Business Wire) -9.35%
Oct-30-24 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Oct-22-24 08:00AM	OmniAb to Report Third Quarter 2024 Financial Results on November 12 (Business Wire)
Aug-26-24 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-08-24 04:05PM	OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights (Business Wire) +5.67%
Jul-25-24 08:00AM	OmniAb to Report Second Quarter 2024 Financial Results on August 8 (Business Wire)
Jun-03-24 04:05PM	OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology (Business Wire)
May-20-24 08:05AM	OmniAb to Participate in the Jefferies Global Healthcare Conference (Business Wire)
May-15-24 04:05PM	OmniAb Presents High-Throughput Single B-cell Screening xPloration Data at the 20th Annual PEGS Boston Summit (Business Wire)
May-12-24 03:24PM	5 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-09-24 08:56PM	OABI Stock Earnings: OmniAb Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	OmniAb Reports First Quarter 2024 Financial Results and Business Highlights (Business Wire)
May-01-24 08:00AM	OmniAb to Participate in Five Investor Conferences in May (Business Wire)
Apr-22-24 08:00AM	OmniAb to Report First Quarter 2024 Financial Results on May 9 (Business Wire)
Mar-21-24 11:31AM	OmniAb, Inc. (NASDAQ:OABI) Q4 2023 Earnings Call Transcript (Insider Monkey) -5.17%
Mar-20-24 08:54PM	OABI Stock Earnings: OmniAb Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:05PM	OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (Business Wire)
Feb-28-24 08:27AM	OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-24 08:00AM	OmniAb to Report Fourth Quarter 2023 Financial Results on March 20 (Business Wire)
Feb-20-24 08:00AM	OmniAb to Participate in Two Investor Conferences in March (Business Wire)
Dec-14-23 04:30PM	OmniAb Presents New Scientific Data on its OmnidAb Platform at the 2023 Antibody Engineering & Therapeutics Conference (Business Wire)
Nov-20-23 12:39PM	OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 05:03AM	Insider Buying: OmniAb Inc CEO Matthew Foehr Acquires 95,000 Shares (GuruFocus.com) +6.32%
Nov-09-23 05:55PM	OmniAb Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at Todays Research & Technology Virtual Event (Business Wire)
09:24AM	OmniAb Inc (OABI) Reports Decline in Q3 Revenue and Widening Net Loss (GuruFocus.com)
08:00AM	OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights (Business Wire)
Nov-02-23 08:00AM	OmniAb to Participate in Two Investor Conferences in November (Business Wire)
Nov-01-23 09:00AM	OmniAb Appoints Steve Love to its Board of Directors (Business Wire)
Oct-31-23 04:28PM	OmniAb Announces Agenda for its Research & Technology Virtual Event (Business Wire)
Oct-26-23 02:32PM	7 of the Best Cheap Stocks to Buy Under $5 in October 2023 (InvestorPlace)
Oct-12-23 08:00AM	OmniAb to Hold Research & Technology Virtual Event on November 9 (Business Wire)
Sep-05-23 08:00AM	OmniAb to Participate in Two Investor Conferences in September (Business Wire)
Aug-15-23 05:20AM	OmniAb, Inc. (NASDAQ:OABI) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-13-23 08:06AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Aug-10-23 04:05PM	OmniAb Reports Second Quarter 2023 Financial Results and Business Highlights (Business Wire) -5.54%
Aug-07-23 04:05PM	OmniAb Announces the Passing of Director Sunil Patel (Business Wire)
Jul-31-23 08:00AM	OmniAb to Report Second Quarter 2023 Financial Results on August 10 (Business Wire)
Jul-17-23 07:35AM	With 60% institutional ownership, OmniAb, Inc. (NASDAQ:OABI) is a favorite amongst the big guns (Simply Wall St.)
Jun-13-23 06:00AM	7 Stocks to Buy for 200% Returns This Year (InvestorPlace) +6.32%
May-18-23 05:09PM	7 Stocks to Buy for Their Massive Upside Potential (InvestorPlace)
May-17-23 04:05PM	OmniAb Launches OmniDeep at the PEGS Boston Conference and Expo (Business Wire)
May-16-23 06:06AM	President of OmniAb Matthew Foehr Buys 22% More Shares \ (Simply Wall St.) +9.12%
May-14-23 08:03AM	OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially (Simply Wall St.)
May-11-23 10:55PM	Q1 2023 OmniAb Inc Earnings Call (Thomson Reuters StreetEvents) +8.36%
07:00AM	OmniAb Reports First Quarter 2023 Financial Results and Business Highlights (Business Wire)
May-05-23 07:14AM	OmniAb, Inc.'s (NASDAQ:OABI) Share Price Matching Investor Opinion (Simply Wall St.)
May-04-23 06:26AM	10 Best Small-Cap Growth Stocks to Buy Now (Insider Monkey)
May-01-23 08:00AM	OmniAb to Report First Quarter 2023 Financial Results on May 11 (Business Wire)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-25-23 08:00AM	OmniAb to Participate in Upcoming Investor Conferences in May (Business Wire)
Apr-19-23 08:30AM	Here's How Much a $1000 Investment in Ligand Pharmaceuticals Made 10 Years Ago Would Be Worth Today (Zacks)
Apr-07-23 10:24PM	OmniAb, Inc. (NASDAQ:OABI) Q4 2022 Earnings Call Transcript (Insider Monkey)
Apr-05-23 06:09AM	OmniAb Full Year 2022 Earnings: Beats Expectations (Simply Wall St.)
Apr-02-23 08:51AM	Insiders of OmniAb, Inc. (NASDAQ:OABI) are up 11% on their US$2.3m purchase after OmniAb, Inc. (NASDAQ:OABI) rose 14% last week (Simply Wall St.)
Mar-31-23 08:40AM	Do Options Traders Know Something About OmniAb (OABI) Stock We Don't? (Zacks)
Mar-30-23 04:05PM	OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights (Business Wire)
Mar-15-23 11:44AM	7 Biotech Stocks That Could Be the Next Big Thing (InvestorPlace)
Mar-09-23 08:00AM	OmniAb to Report Fourth Quarter 2022 Financial Results on March 30 (Business Wire) -5.03%
Mar-08-23 09:53AM	These 2 Strong Buy Penny Stocks Are Poised for a Massive Rally, Say Analysts (TipRanks)
Feb-23-23 07:49AM	Ligand's (LGND) Q4 Sales & Earnings Top, View Raised, Stock Up (Zacks)
Feb-07-23 08:00AM	OmniAb to Participate in Three Upcoming Investor Conferences (Business Wire)
Feb-01-23 06:56AM	With 44% stake, OmniAb, Inc. (NASDAQ:OABI) seems to have captured institutional investors' interest (Simply Wall St.)
Dec-16-22 12:39PM	Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says (Benzinga)
Dec-01-22 08:47AM	Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies (HSB-1940) against PD-1, by combining Quatramers with OmniAbs Picobodies, via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets (GlobeNewswire) -5.37%
Nov-15-22 07:00AM	OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights (Business Wire) -10.00%
Nov-03-22 08:00AM	OmniAb to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-02-22 07:00AM	OmniAb, Inc. to Ring Nasdaq Stock Market Opening Bell (Business Wire) -60.65%

OmniAb, Inc. operates as a drug discovery company. It focuses on developing human monoclonal and bispecific therapeutic antibodies. Its platform includes the biological intelligence of its transgenic animals, including OmniRat, OmniChicken and OmniMouse. The company was founded on December 14, 2015 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Berkman Charles S	Chief Legal Officer	Dec 07 '25	Option Exercise	0.00	15,621	0	385,115	Dec 09 09:02 AM
Berkman Charles S	Chief Legal Officer	Dec 08 '25	Sale	1.96	8,044	15,766	377,071	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 07 '25	Option Exercise	0.00	46,500	0	276,610	Dec 09 09:02 AM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Dec 08 '25	Sale	1.96	23,922	46,887	252,688	Dec 09 09:02 AM
FOEHR MATTHEW W	President and CEO	Dec 07 '25	Option Exercise	0.00	26,554	0	4,373,749	Dec 09 09:01 AM
FOEHR MATTHEW W	President and CEO	Dec 08 '25	Sale	1.96	13,666	26,785	4,360,083	Dec 09 09:01 AM
GUSTAFSON KURT A	Officer	Dec 08 '25	Proposed Sale	1.96	23,922	46,910		Dec 08 07:17 PM
FOEHR MATTHEW W	Officer	Dec 08 '25	Proposed Sale	1.96	13,666	26,798		Dec 08 07:15 PM
Berkman Charles S	Officer	Dec 08 '25	Proposed Sale	1.96	8,044	15,774		Dec 08 07:14 PM
HIGGINS JOHN L	Director	Nov 07 '25	Buy	1.38	41,038	56,632	2,929,148	Nov 10 08:30 AM
HIGGINS JOHN L	Director	Nov 06 '25	Buy	1.41	36,223	51,074	2,888,110	Nov 10 08:30 AM
Cochran Jennifer R.	Director	May 15 '25	Buy	1.52	30,000	45,600	145,274	May 15 04:02 PM
Love Steven	Director	May 14 '25	Buy	1.46	25,000	36,500	38,333	May 14 05:04 PM
HIGGINS JOHN L	Director	May 12 '25	Buy	1.44	65,000	93,600	2,831,887	May 13 05:52 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Option Exercise	0.00	36,458	0	3,815,618	Apr 07 08:17 PM
FOEHR MATTHEW W	President and CEO	Apr 07 '25	Sale	2.00	19,382	38,764	3,796,236	Apr 07 08:17 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Option Exercise	0.00	13,542	0	370,418	Apr 07 08:10 PM
Berkman Charles S	Chief Legal Officer	Apr 07 '25	Sale	2.00	7,206	14,412	363,212	Apr 07 08:10 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Option Exercise	0.00	13,542	0	231,034	Apr 07 08:09 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 07 '25	Sale	2.00	7,206	14,412	223,828	Apr 07 08:09 PM
GUSTAFSON KURT A	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 08:04 PM
FOEHR MATTHEW W	Officer	Apr 07 '25	Proposed Sale	2.00	19,382	38,715		Apr 07 08:00 PM
Berkman Charles S	Officer	Apr 07 '25	Proposed Sale	2.00	7,206	14,396		Apr 07 07:56 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Option Exercise	0.00	23,244	0	229,455	Apr 01 08:43 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Apr 01 '25	Sale	2.37	11,963	28,352	217,492	Apr 01 08:43 PM
GUSTAFSON KURT A	Officer	Apr 01 '25	Proposed Sale	2.37	11,963	28,351		Apr 01 07:16 PM
HIGGINS JOHN L	Director	Mar 21 '25	Buy	2.28	4,000	9,120	2,766,887	Mar 21 07:58 PM
HIGGINS JOHN L	Director	Mar 20 '25	Buy	2.35	125,750	295,512	2,762,887	Mar 20 08:15 PM
GUSTAFSON KURT A	Executive VP, Finance and CFO	Feb 19 '25	Sale	3.67	7,255	26,626	206,211	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 19 '25	Sale	3.67	19,522	71,646	3,779,160	Feb 19 08:51 PM
FOEHR MATTHEW W	President and CEO	Feb 18 '25	Sale	3.68	13,964	51,388	3,798,682	Feb 19 08:51 PM
Berkman Charles S	Chief Legal Officer	Feb 18 '25	Sale	3.68	8,215	30,231	364,131	Feb 19 08:50 PM
Berkman Charles S	Chief Legal Officer	Feb 19 '25	Sale	3.67	7,255	26,626	356,876	Feb 19 08:50 PM
GUSTAFSON KURT A	Officer	Feb 19 '25	Proposed Sale	3.68	5,188	19,092		Feb 18 08:36 PM
FOEHR MATTHEW W	Officer	Feb 18 '25	Proposed Sale	3.68	13,964	51,390		Feb 18 08:30 PM
Berkman Charles S	Officer	Feb 18 '25	Proposed Sale	3.68	8,215	30,232		Feb 18 08:28 PM

Open in Screener

LGND

Ligand Pharmaceuticals, Inc

Feb 13 • 04:00PM ET

183.83

+2.18 1.20 %

Healthcare • Biotechnology • USA • NASD

LGND Ligand Pharmaceuticals, Inc daily Stock Chart

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR VTI IWM VB VBR VXF SPSM IJT IWN VTWO

Index	RUT	P/E	88.48	EPS (ttm)	2.08	Insider Own	2.41%	Shs Outstand	19.66M	Perf Week	-3.47%
Market Cap	3.62B	Forward P/E	21.84	EPS next Y	8.42	Insider Trans	-5.07%	Shs Float	19.21M	Perf Month	-6.47%
Enterprise Value	3.40B	PEG	1.17	EPS next Q	1.50	Inst Own	105.82%	Short Float	6.68%	Perf Quarter	-10.59%
Income	48.58M	P/S	14.40	EPS this Y	32.06%	Inst Trans	4.36%	Short Ratio	5.79	Perf Half Y	19.53%
Sales	251.23M	P/B	3.80	EPS next Y	11.03%	ROA	4.00%	Short Interest	1.28M	Perf YTD	-2.77%
Book/sh	48.34	P/C	5.44	EPS next 5Y	18.69%	ROE	5.42%	52W High	212.49 -13.49%	Perf Year	61.35%
Cash/sh	33.77	P/FCF	118.07	EPS past 3/5Y	- -	ROIC	3.47%	52W Low	93.58 96.44%	Perf 3Y	157.86%
Dividend Est.	-	EV/EBITDA	52.30	Sales past 3/5Y	-11.55% 6.80%	Gross Margin	81.19%	Volatility	4.54% 4.01%	Perf 5Y	65.19%
Dividend TTM	-	EV/Sales	13.55	EPS Y/Y TTM	-9.12%	Oper. Margin	11.48%	ATR (14)	7.97	Perf 10Y	231.38%
Dividend Ex-Date	Jul 02, 2010	Quick Ratio	24.30	Sales Y/Y TTM	64.83%	Profit Margin	19.34%	RSI (14)	39.27	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	24.69	EPS Q/Q	1559.91%	SMA20	-4.94%	Beta	1.22	Target Price	243.44
Payout	-	Debt/Eq	0.47	Sales Q/Q	122.85%	SMA50	-5.01%	Rel Volume	0.58	Prev Close	181.65
Employees	68	LT Debt/Eq	0.47	Earnings	Feb 26 BMO	SMA200	14.25%	Avg Volume	221.43K	Price	183.83
IPO	Nov 18, 1992	Option/Short	Yes / Yes	EPS/Sales Surpr.	60.24% 96.55%	Trades		Volume	129,220	Change	1.20%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Citigroup	Buy	$270
Apr-10-25	Initiated	Stifel	Buy	$143
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260

Show Previous Ratings

Feb-12-26 07:00AM	Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-04-26 07:00AM	Ligand to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-13-26 04:36PM	Travere, Ligand Hammered On A Surprise Delay For Their Linchpin Drug (Investor's Business Daily) -8.72%
Jan-12-26 10:32AM	Gamble on Huge Gains with These 3 Best Biotech Stocks to Buy for 2026 (Barchart)
07:13AM	Loading…
Jan-08-26 07:13AM	Dow Jones Futures Fall; Lockheed, Defense Giants Bounce On $1.5 Trillion Trump 'Dream Military' (Investor's Business Daily)
Jan-07-26 05:05PM	Dow Jones Futures: Stock Market Fades From Highs; Eli Lilly, Google Lead New Buys (Investor's Business Daily)
Dec-09-25 07:00AM	Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance (GlobeNewswire)
Nov-20-25 01:34PM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year (Investor's Business Daily)
Nov-19-25 08:11AM	What Makes Ligand Pharmaceuticals (LGND) an Investment Choice? (Insider Monkey)
Nov-18-25 08:03AM	Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 88% This Year (Investor's Business Daily)
Nov-10-25 05:31AM	Pelthos acquires US rights to Xepi cream from Biofrontera and Ferrer (Pharmaceutical Technology)
Nov-06-25 07:14AM	Ligand: Q3 Earnings Snapshot (Associated Press Finance) +9.37%
07:00AM	Ligand Reports Third Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Oct-30-25 04:01PM	Ligand to Participate in November Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Oct-23-25 07:00AM	Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
Oct-16-25 07:00AM	Ligand to Host Investor Day on December 9, 2025 (GlobeNewswire)
Oct-09-25 07:00AM	Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients (GlobeNewswire)
Aug-19-25 04:00PM	Ligand to Participate in September Investor Conferences (GlobeNewswire)
Aug-14-25 04:00PM	Ligand Announces Closing of Convertible Senior Notes Offering (GlobeNewswire)
Aug-12-25 08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-11-25 11:46PM	Ligand Announces Pricing of $400 Million Convertible Senior Notes Offering (GlobeNewswire)
07:00AM	Ligand Announces Proposed Offering of $400 Million of Convertible Senior Notes Due 2030 (GlobeNewswire)
Aug-07-25 07:24AM	Ligand: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Ligand Reports Second Quarter 2025 Financial Results and Raises Guidance (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Jul-31-25 04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-24-25 07:00AM	Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-17-25 02:10PM	Ligand Pharmaceuticals Stock Earns 84 RS Rating (Investor's Business Daily) +6.13%
Jul-12-25 02:00PM	Top 3 small-cap stock picks while navigating trade uncertainty (Yahoo Finance Video)
10:43AM	Loading…
Jul-10-25 10:43AM	LGND Raises $9M to Make Earth Data Intuitive and Actionable (PR Newswire)
09:58AM	LGND wants to make ChatGPT for the Earth (TechCrunch)
08:00AM	Ligand Partner Pelthos Therapeutics Launches ZELSUVMI (GlobeNewswire)
Jul-03-25 07:17AM	Ligands LNHC concludes merger with CHRO (Pharmaceutical Technology)
Jul-02-25 07:00AM	Pelthos Therapeutics Completes Merger with Channel Therapeutics and Closes $50.1 Million Private Placement (GlobeNewswire)
07:00AM	Ligand Announces Completion of Pelthos Therapeutics Merger with Channel Therapeutics (GlobeNewswire)
Jun-11-25 07:00AM	Ligand Announces 2025 Investor Day in New York City (GlobeNewswire)
May-14-25 07:00AM	Ligand to Ring the Nasdaq Opening Bell on May 19, 2025 (GlobeNewswire)
May-08-25 07:44AM	Ligand Pharmaceuticals Reiterates FY25 Outlook - Update (RTT News)
07:00AM	Ligand Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
12:09PM	Ligand Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
May-01-25 07:00AM	Ligand to Participate in May Investor Conferences (GlobeNewswire)
Apr-24-25 07:00AM	Ligand to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-20-25 09:35AM	Revisiting Ligand Pharmaceuticals, Ready To Accumulate If Shares Dip Below $100 (Seeking Alpha)
Apr-17-25 06:00AM	Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics (GlobeNewswire)
Apr-03-25 11:50AM	Bumbershoot Holdings 2024 Investor Letter (Seeking Alpha) -5.17%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
07:30AM	Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-25 07:00AM	Ligand to Participate in March Investor Conferences (GlobeNewswire) -8.22%
Feb-27-25 07:00AM	Ligand Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-25-25 07:00AM	Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences (GlobeNewswire)
Feb-13-25 07:00AM	Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (Business Wire)
Feb-06-25 07:00AM	Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company that involves clinical development and commercialization of high-value medicines. Its platforms, Captisol and NITRICI, offer technology with broad applicability in drug development to a large network of biopharmaceutical partners, including the largest pharmaceutical manufacturers in the world. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
KOZARICH JOHN W	Director	Feb 02 '26	Sale	195.91	467	91,490	43,187	Feb 04 05:18 PM
KOZARICH JOHN W	Director	Feb 02 '26	Proposed Sale	192.18	467	89,748		Feb 02 04:12 PM
KOZARICH JOHN W	Director	Jan 02 '26	Sale	189.58	467	88,532	43,654	Jan 06 07:47 PM
KOZARICH JOHN W	Director	Jan 02 '26	Proposed Sale	188.60	467	88,076		Jan 02 04:04 PM
Espinoza Octavio	Chief Financial Officer	Dec 16 '25	Option Exercise	69.00	2,381	164,298	28,567	Dec 18 04:19 PM
Espinoza Octavio	Chief Financial Officer	Dec 12 '25	Sale	188.31	1,804	339,711	26,186	Dec 16 06:36 PM
OCTAVIO ESPINOZA	Officer	Dec 12 '25	Proposed Sale	188.31	1,804	339,711		Dec 12 05:22 PM
Aryeh Jason	Director	Dec 08 '25	Option Exercise	69.51	2,034	141,383	71,323	Dec 08 07:38 PM
KOZARICH JOHN W	Director	Dec 01 '25	Sale	195.84	467	91,457	44,121	Dec 03 05:08 PM
KOZARICH JOHN W	Director	Dec 01 '25	Proposed Sale	199.88	467	93,344		Dec 01 04:08 PM
Gray Nancy Ryan	Director	Nov 07 '25	Option Exercise	69.58	6,571	457,185	11,650	Nov 12 04:45 PM
Gray Nancy Ryan	Director	Nov 07 '25	Sale	205.45	6,571	1,350,012	8,094	Nov 12 04:45 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Option Exercise	67.78	4,179	283,232	32,869	Nov 12 04:44 PM
LAMATTINA JOHN L	Director	Nov 07 '25	Sale	205.45	4,179	858,576	30,724	Nov 12 04:44 PM
NANCY GRAY	Director	Nov 07 '25	Proposed Sale	205.45	6,571	1,350,012		Nov 07 05:05 PM
JOHN L LAMATTINA	Director	Nov 07 '25	Proposed Sale	205.45	4,179	858,576		Nov 07 04:05 PM
KOZARICH JOHN W	Director	Nov 03 '25	Sale	191.05	467	89,219	44,588	Nov 05 05:22 PM
KOZARICH JOHN W	Director	Nov 03 '25	Proposed Sale	191.05	467	89,219		Nov 03 04:05 PM
KOZARICH JOHN W	Director	Oct 01 '25	Sale	179.44	467	83,800	45,055	Oct 03 04:45 PM
KOZARICH JOHN W	Director	Oct 01 '25	Proposed Sale	176.68	467	82,510		Oct 01 04:09 PM
Aryeh Jason	Director	Sep 23 '25	Sale	170.81	10,000	1,708,088	69,289	Sep 24 05:11 PM
JASON M ARYEH	Director	Sep 23 '25	Proposed Sale	170.81	10,000	1,708,087		Sep 23 04:50 PM
Aryeh Jason	Director	Sep 17 '25	Proposed Sale	168.50	10,000	1,685,000		Sep 17 12:41 PM
KOZARICH JOHN W	Director	Sep 02 '25	Sale	162.26	467	75,775	45,522	Sep 04 05:47 PM
KOZARICH JOHN W	Director	Sep 02 '25	Proposed Sale	161.71	467	75,518		Sep 02 04:16 PM
KOZARICH JOHN W	Director	Aug 01 '25	Sale	131.88	467	61,586	45,989	Aug 05 05:03 PM
KOZARICH JOHN W	Director	Aug 01 '25	Proposed Sale	131.00	467	61,177		Aug 01 04:04 PM
KOZARICH JOHN W	Director	Jul 10 '25	Sale	125.00	934	116,750	46,456	Jul 11 06:17 PM
KOZARICH JOHN W	Officer	Jul 10 '25	Proposed Sale	125.00	934	116,750		Jul 10 05:08 PM
Reardon Andrew	CLO & Secretary	Jun 23 '25	Sale	114.08	500	57,042	31,903	Jun 24 08:29 PM
ANDREW THOMAS REARDON	Officer	Jun 23 '25	Proposed Sale	114.08	500	57,042		Jun 23 05:07 PM
Reardon Andrew	CLO & Secretary	Jun 10 '25	Sale	114.54	500	57,271	32,403	Jun 12 05:51 PM
ANDREW THOMAS REARDON	Officer	Jun 10 '25	Proposed Sale	114.54	500	57,271		Jun 10 06:49 PM
Reardon Andrew	CLO & Secretary	May 15 '25	Sale	104.00	1,000	104,000	32,903	Jun 02 08:06 PM
ANDREW THOMAS REARDON	Officer	May 15 '25	Proposed Sale	104.00	1,000	104,000		May 15 05:14 PM
Davis Todd C	Chief Executive Officer	May 09 '25	Buy	105.20	9,510	1,000,456	161,234	May 13 08:05 PM
Espinoza Octavio	Chief Financial Officer	May 09 '25	Buy	104.06	1,500	156,090	27,932	May 13 08:04 PM
Sabba Stephen L	Director	Apr 01 '25	Option Exercise	52.30	2,406	125,834	32,584	Apr 16 09:34 AM
Sabba Stephen L	Director	Mar 18 '25	Proposed Sale	106.00	2,406	255,036		Mar 18 04:01 PM
Espinoza Octavio	Chief Financial Officer	Mar 04 '25	Sale	115.03	5,000	575,148	18,879	Mar 06 06:55 PM
Espinoza Octavio	Officer	Mar 04 '25	Proposed Sale	115.03	5,000	575,149		Mar 04 05:10 PM

Open in Screener

VKTX

Viking Therapeutics Inc

Feb 13 • 04:00PM ET

29.00

-1.49 -4.89 %

Healthcare • Biotechnology • USA • NASD

VKTX Viking Therapeutics Inc daily Stock Chart

Peers: MDGL AKRO GLMD AKBA ATON ARDX BOLD TVRD EYPT KYNB

| Held by: VTI VB XBI VBK VXF SCHA IWR VHT IWD IWS

Index	-	P/E	-	EPS (ttm)	-3.18	Insider Own	2.95%	Shs Outstand	114.79M	Perf Week	1.97%
Market Cap	3.35B	Forward P/E	-	EPS next Y	-4.57	Insider Trans	-12.25%	Shs Float	112.14M	Perf Month	-15.55%
Enterprise Value	2.65B	PEG	-	EPS next Q	-1.00	Inst Own	61.83%	Short Float	23.24%	Perf Quarter	-28.89%
Income	-359.64M	P/S	-	EPS this Y	-32.23%	Inst Trans	-2.05%	Short Ratio	8.41	Perf Half Y	-27.93%
Sales	0.00M	P/B	5.21	EPS next Y	-8.41%	ROA	-44.29%	Short Interest	26.06M	Perf YTD	-17.57%
Book/sh	5.57	P/C	4.75	EPS next 5Y	-9.28%	ROE	-47.34%	52W High	43.15 -32.79%	Perf Year	-1.69%
Cash/sh	6.11	P/FCF	-	EPS past 3/5Y	-52.71% -42.46%	ROIC	-56.28%	52W Low	18.92 53.28%	Perf 3Y	172.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.73% 6.44%	Perf 5Y	245.65%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-215.49%	Oper. Margin	-	ATR (14)	2.16	Perf 10Y	1646.99%
Dividend Ex-Date	-	Quick Ratio	9.33	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.54	Recom	1.11
Dividend Gr. 3/5Y	- -	Current Ratio	9.33	EPS Q/Q	-334.74%	SMA20	-4.87%	Beta	0.77	Target Price	92.94
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-12.78%	Rel Volume	0.95	Prev Close	30.49
Employees	53	LT Debt/Eq	0.00	Earnings	Feb 11 AMC	SMA200	-7.41%	Avg Volume	3.10M	Price	29.00
IPO	Apr 29, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-55.02% -	Trades		Volume	2,931,412	Change	-4.89%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-29-25	Initiated	Canaccord Genuity	Buy	$106
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$104
Apr-08-25	Initiated	Goldman	Neutral	$30
Feb-13-25	Initiated	Scotiabank	Sector Outperform	$102
Feb-07-25	Initiated	Citigroup	Neutral	$38
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy	$109
Nov-04-24	Reiterated	H.C. Wainwright	Buy	$90 → $102
Sep-11-24	Initiated	JP Morgan	Overweight	$80
Jun-27-24	Initiated	Morgan Stanley	Overweight	$105
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy	$115 → $116
Mar-26-24	Reiterated	Oppenheimer	Outperform	$116 → $138
Mar-07-24	Initiated	Jefferies	Buy	$110
Feb-28-24	Reiterated	Oppenheimer	Outperform	$46 → $116
May-31-23	Resumed	ROTH MKM	Buy	$32
Mar-28-23	Reiterated	Maxim Group	Buy	$15 → $25
Mar-17-23	Initiated	Stifel	Buy	$22
Jul-29-21	Resumed	BTIG Research	Buy	$20
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform	$27 → $12
Jun-05-20	Initiated	BMO Capital Markets	Outperform	$14

Show Previous Ratings

Feb-13-26 11:26AM	Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market (PR Newswire)
Feb-12-26 11:31AM	Viking Therapeutics Stock Soars: What's Driving The Momentum? (Benzinga) +6.80%
10:07AM	Stocks Mixed on Strength in Chipmakers and Weakness in Cisco Systems (Barchart)
08:42AM	How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report (Zacks)
08:30AM	Viking Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby)
08:03AM	Loading…
08:03AM	VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates (Zacks)
12:03AM	Viking Therapeutics Inc (VKTX) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com)
Feb-11-26 06:02PM	Viking Therapeutics Q4 Earnings Call Highlights (MarketBeat)
05:13PM	Cisco Systems, Applovin, Viking: After-Hours Movers (Yahoo Finance Video)
04:33PM	Viking Therapeutics Stock Climbs After Q4 Report: Details (Benzinga)
04:16PM	Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update (PR Newswire)
09:54AM	Is Novo Nordisk's Turnaround Story at Risk After Weak 2026 Outlook? (Zacks)
Feb-10-26 10:49AM	Eli Lilly's 2025 Surge Sets the Stage for Another Big Year in 2026 (Zacks)
Feb-09-26 11:30AM	Robinhood, AppLovin, Rivian and More Stocks With Earnings This Week (Benzinga)
10:12AM	Hims & Hers Halts Knockoff Wegovy Pill After Just Two Days: Here's Why (Investor's Business Daily)
09:55AM	Loading…
09:55AM	Novo Nordisk Stock Whipsawed by GLP-1 Pill Fears: Relief Ahead? (Zacks)
Feb-07-26 05:22PM	Hims & Hers Health Stops Offering Knockoff Wegovy Pill Amid FDA Crackdown (Investor's Business Daily)
Feb-04-26 04:05PM	Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2025 on February 11, 2026 (PR Newswire) -11.06%
Feb-03-26 07:08PM	The Smartest Growth Stock to Buy With $30 Right Now (Motley Fool)
Feb-02-26 11:00AM	AZN Obesity Pipeline to Get a Boost From Deal With China's CSPC (Zacks)
Jan-30-26 05:45PM	Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market (Zacks)
10:06AM	Novo Nordisk Before Q4 Earnings: How Should Investors Play the Stock? (Zacks)
08:47AM	Viking Therapeutics to Report Q4 Earnings: Here's What to Know (Zacks)
Jan-28-26 09:09AM	Roche Reports Upbeat Efficacy Data From Phase II Obesity Study (Zacks)
Jan-27-26 01:35PM	2 Biotech Stocks Set to Rebound in 2026 (Motley Fool)
09:41AM	Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet? (Zacks)
Jan-26-26 11:35AM	Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? (Motley Fool)
09:15AM	How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q4 Results? (Zacks)
03:14AM	Viking Therapeutics, Inc. (VKTX) Advances Obesity Drug Development and Expands Metabolic Disease Pipeline (Insider Monkey)
Jan-24-26 08:35PM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
01:35PM	Loading…
01:35PM	The Best Stocks to Invest $40 in to Start the New Year Off Right (Motley Fool)
Jan-23-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts (Zacks) -5.49%
05:30AM	Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 (Motley Fool)
Jan-22-26 05:50PM	Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts (Zacks)
Jan-21-26 03:41PM	2 Bargain Stocks You Can Buy for Less Than $100 Right Now (Motley Fool)
10:50AM	1 Stock That Could Soar by 175%, According to Wall Street (Motley Fool)
Jan-20-26 03:25PM	What Happened to Viking Therapeutics in 2025, And Is it a Buy for 2026? (Motley Fool)
08:28AM	3 Biotech Stocks That Look Like "Sure-Fire" Winners in 2026 (MarketBeat)
Jan-19-26 03:23PM	Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (MarketBeat)
09:59AM	Is Novo Nordisk's Oral Wegovy Driving Strong Early US Demand Already? (Zacks)
Jan-16-26 10:47AM	LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling (Zacks) +6.40%
Jan-15-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks) -7.16%
01:11PM	Wall Street Soars Near Records, AMD And ASML Jump 6%: What's Moving Markets Thursday? (Benzinga)
10:17AM	How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results? (Zacks)
05:10AM	Viking Therapeutics (VKTX) Soars 11.9% on Strong Weight Loss Market Outlook (Insider Monkey)
Jan-14-26 01:25PM	Stocks Drop, Energy Sector Rises As Crude Eyes 6th Day Of Gains: What's Moving Markets Wednesday? (Benzinga) +11.89%
Jan-13-26 09:58AM	Novo Nordisk Soars 19% in a Month: How Should You Play the Stock? (Zacks)
09:06AM	Jim Cramer Says "I'm a Eli Lilly Guy" When Asked About Viking Therapeutics (Insider Monkey)
Jan-12-26 07:00AM	Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity (PR Newswire)
Jan-09-26 05:45PM	Viking Therapeutics, Inc. (VKTX) Outperforms Broader Market: What You Need to Know (Zacks)
09:58AM	VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug (Zacks)
07:12AM	Viking Therapeutics completes enrollment in trial of VK2735 (TipRanks)
Jan-08-26 08:38PM	Lightning Round: QXO is a buy, says Jim Cramer (CNBC TV)
09:30AM	Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet (Zacks)
07:00AM	Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity (PR Newswire)
Jan-07-26 07:00AM	Viking Therapeutics Announces Appointment of Neil Aubuchon as Chief Commercial Officer (PR Newswire)
Jan-06-26 09:41AM	Can the US Launch of NVO's Wegovy Pill Reignite Momentum in 2026? (Zacks)
Jan-05-26 05:50PM	Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks) -9.26%
04:03PM	Viking Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
10:37AM	LLY Up 28% in 3 Months: Is it the Right Time to Invest in the Stock? (Zacks)
08:34AM	Will NVO's Wegovy Pill Approval for Obesity be a Game Changer in 2026? (Zacks)
Jan-02-26 09:01AM	Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III (Zacks)
Dec-31-25 09:15AM	2 Beaten-Down Stocks That Could Bounce Back in 2026 (Motley Fool)
08:07AM	The End of Shots? 5 Biotech Stocks Rethinking Diabetes (PR Newswire)
Dec-30-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know (Zacks)
Dec-29-25 02:34PM	This Small But Mighty Stock Could Surprise Investors in 2026 (Barchart)
Dec-24-25 10:49AM	NVO's First Oral Obesity Pill Approval: What Does it Mean for Lilly? (Zacks)
Dec-23-25 05:45PM	Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
04:01PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
10:46AM	Novo Nordisk Wins FDA Nod for Oral Wegovy in Obesity, Stock Up (Zacks)
09:30AM	Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy? (Zacks)
08:58AM	Premarket Movers: Albemarle Gaining Momentum on Lithium Boom (24/7 Wall St.)
Dec-22-25 06:46PM	Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug (Investor's Business Daily)
06:50AM	Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX) (Insider Monkey)
Dec-18-25 01:13PM	Viking Therapeutics, Inc. (VKTX): A Bull Case Theory (Insider Monkey)
12:35PM	2 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
09:53AM	Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share? (Zacks)
Dec-16-25 01:35PM	1 Bold Prediction for Viking Therapeutics in 2026 (Motley Fool)
10:50AM	2 Monster Stocks in the Making to Buy and Hold (Motley Fool)
Dec-15-25 11:11PM	Viking Therapeutics (VKTX) Deemed 'Extremely Attractive' and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development (Insider Monkey)
05:45PM	Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
10:32AM	CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval (Zacks)
Dec-13-25 04:30AM	My Top 10 Stocks to Buy for 2026 (Motley Fool)
Dec-12-25 11:17AM	Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win (Zacks)
10:37AM	NVO Down 42% Year to Date: Is This an Indication to Sell the Stock? (Zacks)
Dec-11-25 04:28PM	Eli Lilly Puts Obesity Field 'On Notice' With Best-Ever Weight Loss (Investor's Business Daily)
08:10AM	Eli Lilly's Experimental Obesity Drug Cut Weight By 23.7% (Investor's Business Daily)
07:44AM	This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street (Insider Monkey)
07:35AM	3 Underrated Growth Stocks That Look Like Great Buys Heading Into 2026 (Motley Fool)
Dec-10-25 10:17AM	Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies? (Zacks)
07:43AM	PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence (Zacks)
07:10AM	Bullish Analysts Just Cant Quit Strategy Shares After 60% Rout (Bloomberg)
Dec-09-25 09:27AM	GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron (Zacks)
Dec-04-25 12:21PM	Why This FDA Shake-Up Rattled Medpace And Iqvia, But Buoyed Viking Therapeutics (Investor's Business Daily) +8.92%
11:42AM	LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock (Zacks)
Dec-03-25 09:26AM	Can LLY Strengthen Its Lead as GLP-1 Price Cuts Reshape the Market? (Zacks)
Dec-02-25 12:28PM	LLY Lowers Prices of Zepbound Vials for Cash Buyers on DTC Website (Zacks)
Dec-01-25 09:26AM	VKTX Stock Rises 34% in Three Months: Here's What You Should Know (Zacks) -6.14%
Nov-29-25 01:08PM	Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating (Insider Monkey)
Nov-28-25 09:30AM	Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It? (Zacks)

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ZANTE GREG	Chief Financial Officer	Jan 05 '26	Sale	32.90	57,661	1,896,969	189,891	Jan 05 08:31 PM
Mancini Marianna	Chief Operating Officer	Jan 05 '26	Sale	32.98	57,661	1,901,405	409,190	Jan 05 08:31 PM
Lian Brian	President & CEO	Jan 05 '26	Sale	32.96	233,409	7,692,121	2,499,291	Jan 05 08:28 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Option Exercise	3.33	16,000	53,280	148,036	Jan 05 08:25 PM
FOEHR MATTHEW W	Director	Jan 02 '26	Sale	35.11	16,000	561,694	132,036	Jan 05 08:25 PM
MARIANNA MANCINI	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,406		Jan 05 04:32 PM
GREG ZANTE	Officer	Jan 05 '26	Proposed Sale	32.98	57,661	1,901,470		Jan 05 04:30 PM
BRIAN LIAN	Officer	Jan 05 '26	Proposed Sale	32.96	233,409	7,692,134		Jan 05 04:29 PM
MATTHEW W. FOEHR	Director	Jan 02 '26	Proposed Sale	35.11	16,000	561,694		Jan 02 04:46 PM
Mancini Marianna	Chief Operating Officer	Oct 28 '25	Sale	35.00	6,185	216,492	382,467	Oct 28 07:51 PM
Rowland Charles A Jr	Director	Oct 27 '25	Sale	35.57	60,000	2,134,278	30,000	Oct 28 07:49 PM
Lian Brian	President & CEO	Oct 28 '25	Sale	35.01	38,989	1,364,923	2,419,109	Oct 28 07:48 PM
ZANTE GREG	Chief Financial Officer	Oct 28 '25	Sale	35.00	6,185	216,481	173,592	Oct 28 07:47 PM
GREG ZANTE	Officer	Oct 28 '25	Proposed Sale	35.01	6,185	216,531		Oct 28 04:34 PM
MARIANNA MANCINI	Officer	Oct 28 '25	Proposed Sale	35.00	6,185	216,492		Oct 28 04:32 PM
BRIAN LIAN	Officer	Oct 28 '25	Proposed Sale	35.01	38,989	1,364,923		Oct 28 04:27 PM
CHARLES A ROWLAND JR.	Director	Oct 27 '25	Proposed Sale	35.57	60,000	2,134,278		Oct 27 04:25 PM
Lian Brian	President & CEO	Jul 03 '25	Sale	27.80	26,889	747,633	2,388,014	Jul 03 03:31 PM
ZANTE GREG	Chief Financial Officer	Jul 03 '25	Sale	27.76	4,266	118,428	168,660	Jul 03 03:31 PM
Mancini Marianna	Chief Operating Officer	Jul 03 '25	Sale	27.77	4,266	118,473	377,535	Jul 03 03:30 PM
GREG ZANTE	Officer	Jul 03 '25	Proposed Sale	27.76	4,266	118,428		Jul 03 01:07 PM
MARIANNA MANCINI	Officer	Jul 03 '25	Proposed Sale	27.77	4,266	118,473		Jul 03 01:05 PM
BRIAN LIAN	Officer	Jul 03 '25	Proposed Sale	27.80	26,889	747,633		Jul 03 01:01 PM
FOEHR MATTHEW W	Director	Apr 11 '25	Option Exercise	8.00	20,786	166,288	132,036	Apr 14 07:26 PM
Rouan Sarah Kathryn	Director	Mar 31 '25	Buy	24.15	1,240	29,943	1,240	Apr 02 06:29 PM

OABI

OmniAb Inc

LGND

Ligand Pharmaceuticals, Inc

VKTX

Viking Therapeutics Inc

Upgrade your FINVIZ experience